{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T19:17:20Z","timestamp":1794683840163,"version":"4.9.1"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T00:00:00Z","timestamp":1696377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T00:00:00Z","timestamp":1696377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Schizophr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Neuroinflammation contributes to the pathophysiology of various mental illnesses including schizophrenia. We investigated peripheral inflammatory cytokines as a biomarker for predicting symptomatic remission in patients with first-episode schizophrenia. The study included 224 patients aged 15\u201360\u2009years who fulfilled the criteria for schizophrenia spectrum disorder with a treatment duration \u22646\u2009months. Serum levels of tumor necrosis factor (TNF) -\u03b1, interferon-\u03b3, interleukin (IL)-1\u03b1, IL-1\u03b2, IL-6, IL-8, IL-10, and IL-12 were measured. Psychotic symptoms, depressive symptoms, and general functioning were assessed using the Positive and Negative Syndrome Scale, Beck Depression Inventory (BDI), Calgary Depression Scale for Schizophrenia, and Personal and Social Performance scale, respectively. Duration of untreated psychosis (DUP) was also recorded. We investigated the factors associated with remission for each sex in logistic regression analysis. In total, 174 patients achieved remission at the 6-month follow-up (females, 83.5%; males, 70.9%). Remission was associated with older age and lower BDI scores in male patients and with lower TNF-\u03b1 levels and shorter DUP in female patients. Our findings suggest that peripheral inflammatory cytokines may impede early symptomatic remission in female patients with schizophrenia. In addition, depressive symptoms in males and long DUP in females may be poor prognostic factors for early remission in patients with first-episode psychosis.<\/jats:p>","DOI":"10.1038\/s41537-023-00398-1","type":"journal-article","created":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T15:01:54Z","timestamp":1696431714000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Inflammatory markers of symptomatic remission at 6\u2009months in patients with first-episode schizophrenia"],"prefix":"10.1038","volume":"9","author":[{"given":"Honey","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seon-Hwa","family":"Baek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju-Wan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seunghyong","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju-Yeon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7409-6306","authenticated-orcid":false,"given":"Jae-Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9491-1822","authenticated-orcid":false,"given":"Young-Chul","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6739-2163","authenticated-orcid":false,"given":"Sung-Wan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,4]]},"reference":[{"key":"398_CR1","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2016.278","volume":"7","author":"OD Howes","year":"2017","unstructured":"Howes, O. D. & McCutcheon, R. Inflammation and the neural diathesis-stress hypothesis of schizophrenia: a reconceptualization. Transl. Psychiatry 7, e1024 (2017).","journal-title":"Transl. Psychiatry"},{"key":"398_CR2","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1007\/s00213-016-4218-9","volume":"233","author":"MA Calcia","year":"2016","unstructured":"Calcia, M. A. et al. Stress and neuroinflammation: a systematic review of the effects of stress on microglia and the implications for mental illness. Psychopharmacology (Berl.) 233, 1637\u20131650 (2016).","journal-title":"Psychopharmacology (Berl.)"},{"key":"398_CR3","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.biopsych.2008.04.025","volume":"64","author":"BN van Berckel","year":"2008","unstructured":"van Berckel, B. N. et al. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol. Psychiatry 64, 820\u2013822 (2008).","journal-title":"Biol. Psychiatry"},{"key":"398_CR4","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1440-1819.2009.01945.x","volume":"63","author":"A Monji","year":"2009","unstructured":"Monji, A., Kato, T. & Kanba, S. Cytokines and schizophrenia: microglia hypothesis of schizophrenia. Psychiatry Clin. Neurosci. 63, 257\u2013265 (2009).","journal-title":"Psychiatry Clin. Neurosci."},{"key":"398_CR5","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.3389\/fmicb.2019.01057","volume":"10","author":"L Velazquez-Salinas","year":"2019","unstructured":"Velazquez-Salinas, L., Verdugo-Rodriguez, A., Rodriguez, L. L. & Borca, M. V. The role of interleukin 6 during viral infections. Front. Microbiol. 10, 1057 (2019).","journal-title":"Front. Microbiol."},{"key":"398_CR6","doi-asserted-by":"crossref","first-page":"703527","DOI":"10.3389\/fimmu.2021.703527","volume":"12","author":"A Ferro","year":"2021","unstructured":"Ferro, A., Auguste, Y. S. S. & Cheadle, L. Microglia, cytokines, and neural activity: unexpected interactions in brain development and function. Front. Immunol. 12, 703527 (2021).","journal-title":"Front. Immunol."},{"key":"398_CR7","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.biopsych.2007.09.024","volume":"63","author":"S Potvin","year":"2008","unstructured":"Potvin, S. et al. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol. Psychiatry 63, 801\u2013808 (2008).","journal-title":"Biol. Psychiatry"},{"key":"398_CR8","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.psyneuen.2014.03.019","volume":"45","author":"J Dahl","year":"2014","unstructured":"Dahl, J. et al. The plasma levels of various cytokines are increased during ongoing depression and are reduced to normal levels after recovery. Psychoneuroendocrinology 45, 77\u201386 (2014).","journal-title":"Psychoneuroendocrinology"},{"key":"398_CR9","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1176\/appi.ajp.2015.14101358","volume":"173","author":"PS Bloomfield","year":"2016","unstructured":"Bloomfield, P. S. et al. Microglial activity in people at ultra high risk of psychosis and in schizophrenia: an [(11)C]PBR28 pet brain imaging study. Am. J. Psychiatry 173, 44\u201352 (2016).","journal-title":"Am. J. Psychiatry"},{"key":"398_CR10","doi-asserted-by":"crossref","first-page":"608654","DOI":"10.1155\/2013\/608654","volume":"2013","author":"LR Frick","year":"2013","unstructured":"Frick, L. R., Williams, K. & Pittenger, C. Microglial dysregulation in psychiatric disease. Clin. Dev. Immunol. 2013, 608654 (2013).","journal-title":"Clin. Dev. Immunol."},{"key":"398_CR11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/nan.12011","volume":"39","author":"D Boche","year":"2013","unstructured":"Boche, D., Perry, V. H. & Nicoll, Ja. R. Review: activation patterns of microglia and their identification in the human brain. Neuropathol. Appl. Neurobiol. 39, 3\u201318 (2013).","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"398_CR12","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3389\/fnins.2013.00180","volume":"7","author":"U Ratnayake","year":"2013","unstructured":"Ratnayake, U., Quinn, T., Walker, D. W. & Dickinson, H. Cytokines and the neurodevelopmental basis of mental illness. Front. Neurosci. 7, 180 (2013).","journal-title":"Front. Neurosci."},{"key":"398_CR13","doi-asserted-by":"crossref","first-page":"892","DOI":"10.3389\/fpsyt.2019.00892","volume":"10","author":"S Momtazmanesh","year":"2019","unstructured":"Momtazmanesh, S., Zare-Shahabadi, A. & Rezaei, N. Cytokine alterations in schizophrenia: an updated review. Front. Psychiatry 10, 892 (2019).","journal-title":"Front. Psychiatry"},{"key":"398_CR14","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/nyas.12547","volume":"1338","author":"W Hu","year":"2015","unstructured":"Hu, W., MacDonald, M. L., Elswick, D. E. & Sweet, R. A. The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies. Ann. N. Y. Acad. Sci. 1338, 38\u201357 (2015).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"398_CR15","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.pnpbp.2004.11.003","volume":"29","author":"OJG Schiepers","year":"2005","unstructured":"Schiepers, O. J. G., Wichers, M. C. & Maes, M. Cytokines and major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 29, 201\u2013217 (2005).","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"398_CR16","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jpsychires.2006.05.013","volume":"41","author":"SM O\u2019Brien","year":"2007","unstructured":"O\u2019Brien, S. M., Scully, P., Fitzgerald, P., Scott, L. V. & Dinan, T. G. Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J. Psychiatr. Res. 41, 326\u2013331 (2007).","journal-title":"J. Psychiatr. Res."},{"key":"398_CR17","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.biopsych.2013.01.007","volume":"74","author":"A Modabbernia","year":"2013","unstructured":"Modabbernia, A., Taslimi, S., Brietzke, E. & Ashrafi, M. Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies. Biol Psychiatry 74, 15\u201325 (2013).","journal-title":"Biol Psychiatry"},{"key":"398_CR18","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.biopsych.2011.04.013","volume":"70","author":"BJ Miller","year":"2011","unstructured":"Miller, B. J., Buckley, P., Seabolt, W., Mellor, A. & Kirkpatrick, B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 70, 663\u2013671 (2011).","journal-title":"Biol. Psychiatry"},{"key":"398_CR19","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.jpsychires.2013.05.018","volume":"47","author":"K Munkholm","year":"2013","unstructured":"Munkholm, K., Bra\u00fcner, J. V., Kessing, L. V. & Vinberg, M. Cytokines in bipolar disorder vs. healthy control subjects: a systematic review and meta-analysis. J Psychiatr. Res. 47, 1119\u20131133 (2013).","journal-title":"J Psychiatr. Res."},{"key":"398_CR20","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.jpsychires.2012.03.019","volume":"46","author":"M Pedrini","year":"2012","unstructured":"Pedrini, M. et al. Similarities in serum oxidative stress markers and inflammatory cytokines in patients with overt schizophrenia at early and late stages of chronicity. J. Psychiatr. Res. 46, 819\u2013824 (2012).","journal-title":"J. Psychiatr. Res."},{"key":"398_CR21","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.3390\/jpm12071137","volume":"12","author":"S-H Baek","year":"2022","unstructured":"Baek, S.-H. et al. Association between peripheral inflammatory cytokines and cognitive function in patients with first-episode schizophrenia. J. Pers. Med. 12, 1137 (2022).","journal-title":"J. Pers. Med."},{"key":"398_CR22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2020.12.020","volume":"230","author":"D Enache","year":"2021","unstructured":"Enache, D. et al. Peripheral immune markers and antipsychotic non-response in psychosis. Schizophr. Res. 230, 1\u20138 (2021).","journal-title":"Schizophr. Res"},{"key":"398_CR23","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/mp.2016.90","volume":"21","author":"MO Tr\u00e9panier","year":"2016","unstructured":"Tr\u00e9panier, M. O., Hopperton, K. E., Mizrahi, R., Mechawar, N. & Bazinet, R. P. Postmortem evidence of cerebral inflammation in schizophrenia: a systematic review. Mol. Psychiatry 21, 1009\u20131026 (2016).","journal-title":"Mol. Psychiatry"},{"key":"398_CR24","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.schres.2006.09.013","volume":"89","author":"R Emsley","year":"2007","unstructured":"Emsley, R., Rabinowitz, J. & Medori, R., Early Psychosis Global Working Group. Remission in early psychosis: rates, predictors, and clinical and functional outcome correlates. Schizophr. Res. 89, 129\u2013139 (2007).","journal-title":"Schizophr. Res."},{"key":"398_CR25","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.psychres.2014.04.006","volume":"218","author":"RMG Norman","year":"2014","unstructured":"Norman, R. M. G., Manchanda, R. & Windell, D. The prognostic significance of early remission of positive symptoms in first treated psychosis. Psychiatry Res. 218, 44\u201347 (2014).","journal-title":"Psychiatry Res."},{"key":"398_CR26","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.schres.2010.10.020","volume":"125","author":"M Alvarez-Jimenez","year":"2011","unstructured":"Alvarez-Jimenez, M. et al. Prediction of a single psychotic episode: a 7.5-year, prospective study in first-episode psychosis. Schizophr. Res. 125, 236\u2013246 (2011).","journal-title":"Schizophr. Res."},{"key":"398_CR27","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.schres.2008.12.004","volume":"108","author":"A Ciudad","year":"2009","unstructured":"Ciudad, A. et al. Remission in schizophrenia: results from a 1-year follow-up observational study. Schizophr. Res. 108, 214\u2013222 (2009).","journal-title":"Schizophr. Res."},{"key":"398_CR28","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.schres.2005.03.006","volume":"77","author":"RA Lasser","year":"2005","unstructured":"Lasser, R. A., Bossie, C. A., Gharabawi, G. M. & Kane, J. M. Remission in schizophrenia: results from a 1-year study of long-acting risperidone injection. Schizophr. Res. 77, 215\u2013227 (2005).","journal-title":"Schizophr. Res."},{"key":"398_CR29","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1192\/j.eurpsy.2021.2246","volume":"64","author":"A Catalan","year":"2021","unstructured":"Catalan, A. et al. Proportion and predictors of remission and recovery in first-episode psychosis: systematic review and meta-analysis. Eur. Psychiatry 64, e69 (2021).","journal-title":"Eur. Psychiatry"},{"key":"398_CR30","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1176\/appi.ajp.161.3.473","volume":"161","author":"DG Robinson","year":"2004","unstructured":"Robinson, D. G., Woerner, M. G., McMeniman, M., Mendelowitz, A. & Bilder, R. M. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am. J. Psychiatry 161, 473\u2013479 (2004).","journal-title":"Am. J. Psychiatry"},{"key":"398_CR31","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.eurpsy.2003.06.001","volume":"18","author":"J Usall","year":"2003","unstructured":"Usall, J., Ochoa, S., Araya, S. & M\u00e1rquez, M., NEDES Group (Assessment Research Group in Schizophrenia). Gender differences and outcome in schizophrenia: a 2-year follow-up study in a large community sample. Eur. Psychiatry 18, 282\u2013284 (2003).","journal-title":"Eur. Psychiatry"},{"key":"398_CR32","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/eip.12208","volume":"10","author":"S Pang","year":"2016","unstructured":"Pang, S. et al. Gender differences in patients with first-episode psychosis in the Singapore early psychosis intervention programme. Early Interv. Psychiatry 10, 528\u2013534 (2016).","journal-title":"Early Interv. Psychiatry"},{"key":"398_CR33","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.eurpsy.2012.11.005","volume":"29","author":"A Thorup","year":"2014","unstructured":"Thorup, A. et al. Gender differences in first-episode psychosis at 5-year follow-up\u2013two different courses of disease? results from the opus study at 5-year follow-up. Eur. Psychiatry 29, 44\u201351 (2014).","journal-title":"Eur. Psychiatry"},{"key":"398_CR34","doi-asserted-by":"crossref","first-page":"129","DOI":"10.5812\/ijem.6615","volume":"11","author":"J Kulkarni","year":"2013","unstructured":"Kulkarni, J., Gavrilidis, E., Worsley, R., Van Rheenen, T. & Hayes, E. The role of estrogen in the treatment of men with schizophrenia. Int. J. Endocrinol. Metab. 11, 129\u2013136 (2013).","journal-title":"Int. J. Endocrinol. Metab."},{"key":"398_CR35","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000356536","volume":"21","author":"Z Zajkowska","year":"2014","unstructured":"Zajkowska, Z. & Mondelli, V. First-episode psychosis: an inflammatory state? Neuroimmunomodulation 21, 102\u2013108 (2014).","journal-title":"Neuroimmunomodulation"},{"key":"398_CR36","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s00127-014-0887-z","volume":"49","author":"D Baumeister","year":"2014","unstructured":"Baumeister, D., Russell, A., Pariante, C. M. & Mondelli, V. Inflammatory biomarker profiles of mental disorders and their relation to clinical, social and lifestyle factors. Soc. Psychiatry Psychiatr. Epidemiol. 49, 841\u2013849 (2014).","journal-title":"Soc. Psychiatry Psychiatr. Epidemiol."},{"key":"398_CR37","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1038\/mp.2016.3","volume":"21","author":"DR Goldsmith","year":"2016","unstructured":"Goldsmith, D. R., Rapaport, M. H. & Miller, B. J. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol. Psychiatry 21, 1696\u20131709 (2016).","journal-title":"Mol. Psychiatry"},{"key":"398_CR38","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3371\/CSRP.FACA.030813","volume":"9","author":"T Falcone","year":"2015","unstructured":"Falcone, T. et al. Does systemic inflammation play a role in pediatric psychosis? Clin. Schizophr. Relat. Psychoses 9, 65\u201378B (2015).","journal-title":"Clin. Schizophr. Relat. Psychoses"},{"key":"398_CR39","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.bbi.2012.06.010","volume":"31","author":"M Di Nicola","year":"2013","unstructured":"Di Nicola, M. et al. Serum and gene expression profile of cytokines in first-episode psychosis. Brain Behav. Immun. 31, 90\u201395 (2013).","journal-title":"Brain Behav. Immun."},{"key":"398_CR40","doi-asserted-by":"crossref","first-page":"11324","DOI":"10.3390\/ijms231911324","volume":"23","author":"NA Shnayder","year":"2022","unstructured":"Shnayder, N. A. et al. Cytokine imbalance as a biomarker of treatment-resistant schizophrenia. Int. J. Mol. Sci. 23, 11324 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"398_CR41","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1007\/s12035-020-01882-w","volume":"57","author":"M Maes","year":"2020","unstructured":"Maes, M. et al. Increased levels of plasma tumor necrosis factor-\u03b1 mediate schizophrenia symptom dimensions and neurocognitive impairments and are inversely associated with natural Igm directed to malondialdehyde and paraoxonase 1 activity. Mol. Neurobiol. 57, 2333\u20132345 (2020).","journal-title":"Mol. Neurobiol."},{"key":"398_CR42","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.schres.2018.02.048","volume":"199","author":"DR Goldsmith","year":"2018","unstructured":"Goldsmith, D. R. et al. TNF-\u03b1 and IL-6 are associated with the deficit syndrome and negative symptoms in patients with chronic schizophrenia. Schizophr. Res. 199, 281\u2013284 (2018).","journal-title":"Schizophr. Res."},{"key":"398_CR43","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1080\/08820139.2020.1832115","volume":"51","author":"HM Aytac","year":"2022","unstructured":"Aytac, H. M., Ozdilli, K., Tuncel, F. C., Pehlivan, M. & Pehlivan, S. Tumor Necrosis Factor-alpha (TNF-\u03b1) -238 G\/A polymorphism is associated with the treatment resistance and attempted suicide in schizophrenia. Immunol. Invest. 51, 368\u2013380 (2022).","journal-title":"Immunol. Invest."},{"key":"398_CR44","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3109\/15622975.2015.1062552","volume":"16","author":"C Noto","year":"2015","unstructured":"Noto, C. et al. High predictive value of immune-inflammatory biomarkers for schizophrenia diagnosis and association with treatment resistance. World J. Biol. Psychiatry 16, 422\u2013429 (2015).","journal-title":"World J. Biol. Psychiatry"},{"key":"398_CR45","doi-asserted-by":"crossref","first-page":"e78729","DOI":"10.1371\/journal.pone.0078729","volume":"8","author":"JM Ramsey","year":"2013","unstructured":"Ramsey, J. M. et al. Distinct molecular phenotypes in male and female schizophrenia patients. PLoS One 8, e78729 (2013).","journal-title":"PLoS One"},{"key":"398_CR46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2014.03.020","volume":"156","author":"KE O\u2019Connell","year":"2014","unstructured":"O\u2019Connell, K. E., Thakore, J. & Dev, K. K. Pro-inflammatory cytokine levels are raised in female schizophrenia patients treated with clozapine. Schizophr. Res. 156, 1\u20138 (2014).","journal-title":"Schizophr. Res."},{"key":"398_CR47","volume":"10","author":"ST Gal-Oz","year":"2019","unstructured":"Gal-Oz, S. T. et al. Immgen report: sexual dimorphism in the immune system transcriptome. Nat. Commun. 10, 4295 (2019).","journal-title":"Nat. Commun."},{"key":"398_CR48","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nri.2016.90","volume":"16","author":"SL Klein","year":"2016","unstructured":"Klein, S. L. & Flanagan, K. L. Sex differences in immune responses. Nat. Rev. Immunol. 16, 626\u2013638 (2016).","journal-title":"Nat. Rev. Immunol."},{"key":"398_CR49","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.biopsych.2021.01.002","volume":"91","author":"C Lopez-Lee","year":"2022","unstructured":"Lopez-Lee, C., Kodama, L. & Gan, L. Sex differences in neurodegeneration: the role of the immune system in humans. Biol. Psychiatry 91, 72\u201380 (2022).","journal-title":"Biol. Psychiatry"},{"key":"398_CR50","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1192\/bjp.bp.113.127753","volume":"205","author":"M Penttil\u00e4","year":"2014","unstructured":"Penttil\u00e4, M., J\u00e4\u00e4skel\u00e4inen, E., Hirvonen, N., Isohanni, M. & Miettunen, J. Duration of untreated psychosis as predictor of long-term outcome in schizophrenia: systematic review and meta-analysis. Br. J. Psychiatry 205, 88\u201394 (2014).","journal-title":"Br. J. Psychiatry"},{"key":"398_CR51","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.schres.2012.08.017","volume":"142","author":"N Boonstra","year":"2012","unstructured":"Boonstra, N. et al. Duration of untreated psychosis and negative symptoms\u2013a systematic review and meta-analysis of individual patient data. Schizophr. Res. 142, 12\u201319 (2012).","journal-title":"Schizophr. Res."},{"key":"398_CR52","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.schres.2013.11.018","volume":"152","author":"D Fraguas","year":"2014","unstructured":"Fraguas, D. et al. Duration of untreated psychosis predicts functional and clinical outcome in children and adolescents with first-episode psychosis: a 2-year longitudinal study. Schizophr. Res. 152, 130\u2013138 (2014).","journal-title":"Schizophr. Res."},{"key":"398_CR53","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.schres.2007.07.017","volume":"96","author":"L Bechard-Evans","year":"2007","unstructured":"Bechard-Evans, L. et al. Determinants of help-seeking and system related components of delay in the treatment of first-episode psychosis. Schizophr. Res. 96, 206\u2013214 (2007).","journal-title":"Schizophr. Res."},{"key":"398_CR54","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s11414-018-9619-6","volume":"46","author":"JE Hamilton","year":"2019","unstructured":"Hamilton, J. E. et al. Treatment retention among patients participating in coordinated specialty care for first-episode psychosis: a mixed-methods analysis. J. Behav. Health Serv. Res. 46, 415\u2013433 (2019).","journal-title":"J. Behav. Health Serv. Res."},{"key":"398_CR55","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1192\/bjp.bp.112.125500","volume":"203","author":"M Birchwood","year":"2013","unstructured":"Birchwood, M. et al. Reducing duration of untreated psychosis: care pathways to early intervention in psychosis services. Br. J. Psychiatry 203, 58\u201364 (2013).","journal-title":"Br. J. Psychiatry"},{"key":"398_CR56","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1177\/0706743721992679","volume":"66","author":"A Malla","year":"2021","unstructured":"Malla, A. et al. Understanding components of duration of untreated psychosis and relevance for early intervention services in the canadian context: comprendre les composantes de la dur\u00e9e de la psychose non trait\u00e9e et la pertinence de services d\u2019intervention pr\u00e9coce dans le contexte canadien. Can. J. Psychiatry 66, 878\u2013886 (2021).","journal-title":"Can. J. Psychiatry"},{"key":"398_CR57","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1177\/0269881108093883","volume":"23","author":"DL Kelly","year":"2009","unstructured":"Kelly, D. L. et al. Remission in schizophrenia: the relationship to baseline symptoms and changes in symptom domains during a one-year study. J. Psychopharmacol. 23, 436\u2013441 (2009).","journal-title":"J. Psychopharmacol."},{"key":"398_CR58","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.schres.2006.09.027","volume":"90","author":"RR Conley","year":"2007","unstructured":"Conley, R. R., Ascher-Svanum, H., Zhu, B., Faries, D. E. & Kinon, B. J. The burden of depressive symptoms in the long-term treatment of patients with schizophrenia. Schizophr. Res. 90, 186\u2013197 (2007).","journal-title":"Schizophr. Res."},{"key":"398_CR59","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.schres.2016.02.034","volume":"172","author":"ES Gardsjord","year":"2016","unstructured":"Gardsjord, E. S. et al. Subjective quality of life in first-episode psychosis. A ten year follow-up study. Schizophr. Res. 172, 23\u201328 (2016).","journal-title":"Schizophr. Res."},{"key":"398_CR60","first-page":"605","volume":"59","author":"B Golubovi\u0107","year":"2020","unstructured":"Golubovi\u0107, B. et al. Factors associated with depression in patients with schizophrenia. Acta. Clin. Croat. 59, 605\u2013614 (2020).","journal-title":"Acta. Clin. Croat."},{"key":"398_CR61","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3109\/15622975.2011.552633","volume":"13","author":"M Riedel","year":"2012","unstructured":"Riedel, M. et al. Depressive symptoms and their association with acute treatment outcome in first-episode schizophrenia patients: comparing treatment with risperidone and haloperidol. World J. Biol. Psychiatry 13, 30\u201338 (2012).","journal-title":"World J. Biol. Psychiatry"},{"key":"398_CR62","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.schres.2021.03.010","volume":"231","author":"D Fraguas","year":"2021","unstructured":"Fraguas, D. et al. The role of depression in the prediction of a \u2018late\u2019 remission in first-episode psychosis: an analysis of the optimise study. Schizophr. Res. 231, 100\u2013107 (2021).","journal-title":"Schizophr. Res."},{"key":"398_CR63","doi-asserted-by":"crossref","first-page":"106","DOI":"10.4088\/JCP.v69n0114","volume":"69","author":"DO Perkins","year":"2008","unstructured":"Perkins, D. O. et al. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. J. Clin. Psychiatry 69, 106\u2013113 (2008).","journal-title":"J. Clin. Psychiatry"},{"key":"398_CR64","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.euroneuro.2017.06.011","volume":"27","author":"Y Zhu","year":"2017","unstructured":"Zhu, Y. et al. How well do patients with a first episode of schizophrenia respond to antipsychotics: a systematic review and meta-analysis. Eur. Neuropsychopharmacol. 27, 835\u2013844 (2017).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"398_CR65","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/eip.13174","volume":"16","author":"F Iasevoli","year":"2022","unstructured":"Iasevoli, F. et al. Relationships between early age at onset of psychotic symptoms and treatment resistant schizophrenia. Early Interv. Psychiatry 16, 352\u2013362 (2022).","journal-title":"Early Interv. Psychiatry"},{"key":"398_CR66","doi-asserted-by":"crossref","first-page":"505","DOI":"10.31887\/DCNS.2014.16.4\/mcarbon","volume":"16","author":"M Carbon","year":"2014","unstructured":"Carbon, M. & Correll, C. U. Clinical predictors of therapeutic response to antipsychotics in schizophrenia. Dialogues Clin. Neurosci. 16, 505\u2013524 (2014).","journal-title":"Dialogues Clin. Neurosci."},{"key":"398_CR67","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.eurpsy.2007.06.005","volume":"22","author":"L San","year":"2007","unstructured":"San, L., Ciudad, A., Alvarez, E., Bobes, J. & Gilaberte, I. Symptomatic remission and social\/vocational functioning in outpatients with schizophrenia: prevalence and associations in a cross-sectional study. Eur. Psychiatry 22, 490\u2013498 (2007).","journal-title":"Eur. Psychiatry"},{"key":"398_CR68","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1017\/S0033291719001995","volume":"49","author":"N \u00c7akici","year":"2019","unstructured":"\u00c7akici, N., van Beveren, N. J. M., Judge-Hundal, G., Koola, M. M. & Sommer, I. E. C. An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: a meta-analysis. Psychol. Med. 49, 2307\u20132319 (2019).","journal-title":"Psychol. Med."},{"key":"398_CR69","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/schbul\/sbt139","volume":"40","author":"IE Sommer","year":"2014","unstructured":"Sommer, I. E. et al. Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. Schizophr. Bull. 40, 181\u2013191 (2014).","journal-title":"Schizophr. Bull."},{"key":"398_CR70","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.schres.2015.04.002","volume":"168","author":"SM Heringa","year":"2015","unstructured":"Heringa, S. M., Begemann, M. J. H., Goverde, A. J. & Sommer, I. E. C. Sex hormones and oxytocin augmentation strategies in schizophrenia: a quantitative review. Schizophr. Res. 168, 603\u2013613 (2015).","journal-title":"Schizophr. Res."},{"key":"398_CR71","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.euroneuro.2016.11.012","volume":"27","author":"Y-Q Xiang","year":"2017","unstructured":"Xiang, Y.-Q. et al. Adjunctive minocycline for schizophrenia: a meta-analysis of randomized controlled trials. Eur. Neuropsychopharmacol. 27, 8\u201318 (2017).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"398_CR72","doi-asserted-by":"crossref","first-page":"114500","DOI":"10.1016\/j.psychres.2022.114500","volume":"311","author":"X Xu","year":"2022","unstructured":"Xu, X. et al. The efficacy of nutritional supplements for the adjunctive treatment of schizophrenia in adults: a systematic review and network meta-analysis. Psychiatry Res. 311, 114500 (2022).","journal-title":"Psychiatry Res."},{"key":"398_CR73","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1017\/S1092852916000638","volume":"22","author":"M Solmi","year":"2017","unstructured":"Solmi, M. et al. Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia. CNS Spectr. 22, 415\u2013426 (2017).","journal-title":"CNS Spectr."},{"key":"398_CR74","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1177\/0004867419835028","volume":"53","author":"M Cho","year":"2019","unstructured":"Cho, M. et al. Adjunctive use of anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials. Aust. N Z J. Psychiatry 53, 742\u2013759 (2019).","journal-title":"Aust. N Z J. Psychiatry"},{"key":"398_CR75","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.schres.2013.10.011","volume":"151","author":"V Tourjman","year":"2013","unstructured":"Tourjman, V. et al. Antipsychotics\u2019 effects on blood levels of cytokines in schizophrenia: a meta-analysis. Schizophr. Res. 151, 43\u201347 (2013).","journal-title":"Schizophr. Res."},{"key":"398_CR76","unstructured":"Jeste, P. D. V., Lieberman, E. J. A., Fassler, T. D. & Peele S. R. Diagnostic and statistical manual of mental disorders 5th edn., Vol. 947, 220\u2013223 (Am. Psychiatric Publishing Inc., 2013)."},{"key":"398_CR77","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jpsychires.2016.02.017","volume":"77","author":"P Golay","year":"2016","unstructured":"Golay, P. et al. Duration of untreated psychosis: impact of the definition of treatment onset on its predictive value over three years of treatment. J. Psychiatr. Res. 77, 15\u201321 (2016).","journal-title":"J. Psychiatr. Res."},{"key":"398_CR78","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.biopsych.2009.08.040","volume":"67","author":"NC Andreasen","year":"2010","unstructured":"Andreasen, N. C., Pressler, M., Nopoulos, P., Miller, D. & Ho, B.-C. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol. Psychiatry 67, 255\u2013262 (2010).","journal-title":"Biol. Psychiatry"},{"key":"398_CR79","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay, S. R., Fiszbein, A. & Opler, L. A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13, 261\u2013276 (1987).","journal-title":"Schizophr. Bull."},{"key":"398_CR80","first-page":"1090","volume":"40","author":"JS Lee","year":"2001","unstructured":"Lee, J. S. et al. Reliability and validity of the Korean version of the positive and negative syndrome scale. J. Korean Neuropsychiatr. Assoc. 40, 1090\u20131105 (2001).","journal-title":"J. Korean Neuropsychiatr. Assoc."},{"key":"398_CR81","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1176\/appi.ajp.162.3.441","volume":"162","author":"NC Andreasen","year":"2005","unstructured":"Andreasen, N. C. et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am. J. Psychiatry 162, 441\u2013449 (2005).","journal-title":"Am. J. Psychiatry"},{"key":"398_CR82","first-page":"323","volume":"101","author":"PL Morosini","year":"2000","unstructured":"Morosini, P. L., Magliano, L., Brambilla, L., Ugolini, S. & Pioli, R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta. Psychiatr. Scand. 101, 323\u2013329 (2000).","journal-title":"Acta. Psychiatr. Scand."},{"key":"398_CR83","first-page":"497","volume":"17","author":"JG Lee","year":"2006","unstructured":"Lee, J. G. et al. A validation study of the Korean-version of the personal and social performance scale. Korean J. Psychopharmacol. 17, 497\u2013506 (2006).","journal-title":"Korean J. Psychopharmacol."},{"key":"398_CR84","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0272-7358(88)90050-5","volume":"8","author":"AT Beck","year":"1988","unstructured":"Beck, A. T., Steer, R. A. & Carbin, M. G. Psychometric properties of the beck depression inventory: twenty-five years of evaluation. Clin. Psychol. Rev. 8, 77\u2013100 (1988).","journal-title":"Clin. Psychol. Rev."},{"key":"398_CR85","first-page":"201","volume":"14","author":"SH Mo","year":"2008","unstructured":"Mo, S. H. et al. A Study on the reliability and the validity of Korean version of the Beck Depression Inventory-II(BDI-II). J. Korean Soc. Biol. Ther. Psychiatry. 14, 201\u2013212 (2008).","journal-title":"J. Korean Soc. Biol. Ther. Psychiatry."},{"key":"398_CR86","first-page":"446","volume":"44","author":"YG Kim","year":"2005","unstructured":"Kim, Y. G. et al. A Study on the reliability and validity of the Korean version of the Calgary Depression Scale for Schizophrenia (K-CDSS). J. Korean Neuropsychiatr. Ass. 44, 446\u2013455 (2005).","journal-title":"J. Korean Neuropsychiatr. Ass."},{"key":"398_CR87","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0920-9964(90)90005-R","volume":"3","author":"D Addington","year":"1990","unstructured":"Addington, D., Addington, J. & Schissel, B. A depression rating scale for schizophrenics. Schizophr Res. 3, 247\u2013251 (1990).","journal-title":"Schizophr Res."},{"key":"398_CR88","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.psychres.2005.10.002","volume":"144","author":"SW Kim","year":"2006","unstructured":"Kim, S. W. et al. Diagnostic validity of assessment scales for depression in patients with schizophrenia. Psychiatry Res. 144, 57\u201363 (2006).","journal-title":"Psychiatry Res"}],"container-title":["Schizophrenia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41537-023-00398-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41537-023-00398-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41537-023-00398-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T08:04:17Z","timestamp":1700294657000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41537-023-00398-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,4]]},"references-count":88,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["398"],"URL":"https:\/\/doi.org\/10.1038\/s41537-023-00398-1","relation":{},"ISSN":["2754-6993"],"issn-type":[{"value":"2754-6993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,4]]},"assertion":[{"value":"16 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.-W.K. has received research grants from pharmaceutical companies including Handok, Mitsubishi Tanabe, Sumitomo Pharmaceutical, Otsuka, Boehringer-Ingelheim, Allergan, Roche, and Janssen. The funders had no role in the study\u2019s design; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"68"}}